Glofitamab

Therapeutic indications

Glofitamab is indicated for:

Relapsed or refractory diffuse large B-cell lymphoma

Population group: only adults (18 years old or older)

Glofitamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS)

Population group: only adults (18 years old or older)

Glofitamab in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Glofitamab is contraindicated in the following cases:

Lactation

Lactation

Effects on ability to drive and use machines

Effects on ability to drive and use machines

Active infection

Infectious disease

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈